Don't Even Think About Buying Regencell Bioscience Stock Until You See This 1 Red Flag

By Reuben Gregg Brewer – Mar 5, 2026 at 5:00PM ESTKey PointsRegencell Bioscience's investor website explains that it is an early-stage bioscience company working on TCM.It lists indications such as neurocognitive disorders and infectious diseases as areas of interest but doesn't clearly explain what TCM is.Regencell Bioscience (RGC 4.01%) is an early-stage bioscience company. That alone should be enough to keep most investors on the sidelines, given the risks involved if the medicines the company is working on fail to produce positive results. However, there's another small wrinkle here. Regencells Bioscience is working on something it calls TCM. What is TCM? A high-risk, high-return sector Early-stage healthcare companies are fraught with risk. In essence, they are companies that believe something could be a valuable product, but they still have to test it to make sure. It costs huge sums of money to develop, test, and get medicines approved for human use. So companies like Regencell Bioscience often tap the capital markets for cash. Image source: Getty Images. Investors provide money in the hope that whatever the company is working on will eventually turn into a worthwhile product. However, the big risk is that nothing comes of the research. In that situation, investors can be left with nothing to show for their investment but capital losses. That's why only the most aggressive investors and those deeply knowledgeable about the pharmaceutical sector should be even considering Regencell Biosciences. What exactly is Regencell working on? Even then, however, you might want to tread with extreme caution. As the investor site explains: Regencell focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune system, such as COVID-19. ExpandNASDAQ: RGCRegencell BioscienceToday's Change(-4.01%) $-1.02Current Price$24.43Key Data PointsMarket Cap$12BDay's Range$24.10 - $25.2552wk Range$0.10 - $83.60Volume634Avg Vol457K Sounds exciting, but what is TCM? It isn't clear until you look at the annual report for this foreign-based company. There, you are told that "TCM refers to Traditional Chinese Medicine." While there's nothing wrong with traditional Chinese medicine, and it could be a fertile ground for research, it seems a bit risky to invest in a pharmaceutical company that is entirely focused on this category. If there are material opportunities, larger pharmaceutical companies would likely be examining the space. Even if you assume that larger drug makers are missing out on this opportunity, Regencell Biosciences is clear about where its products stand. Again in the annual report: "Currently, our standardized TCM formula for ADHD and ASD patients are under research and development. None of the formula is currently in the process of regulatory approval and commercialization." Basically, there's no product yet, and it's unclear whether there ever will be one. Regencell Bioscience is a shockingly risky investment, and most investors should probably avoid it.Read NextNov 24, 2025 •By Selena MaranjianThis Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)Jun 20, 2025 •By Sean WilliamsPrediction: Wall Street's Latest Stock-Split Stock -- Up 60,120% Year-to-Date -- Is Going to Implode... It's Just a Matter of TimeAbout the AuthorReuben Gregg Brewer is a contributing Motley Fool stock market analyst covering energy, utilities, REITs, and consumer staples. He is the former director of research at Value Line Publishing, where he rose from mutual fund analyst to equity analyst before leading all research operations. Reuben holds a bachelor’s degree in psychology from SUNY Purchase, a master’s in social work from Columbia University, and an MBA from Regis University. He has been featured as a financial expert on CNBC and in the Financial Times, Barron’s, and InvestmentNews.TMFReubenGBrewerStocks MentionedRegencell BioscienceNASDAQ: RGC$24.43(-4.01%)-$1.02*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.